'Small' randomised neo-adjuvant chemotherapy trials in breast cancer reporting on pathological response: More harm than good?

Annals of Oncology

Volumn 16, Issue 9, 2005, Pages 1407-1410

  Bonnefoi, Herve ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIRUBICIN; FLUOROURACIL; NAVELBINE; PACLITAXEL; PREDNISOLONE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ALOPECIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SUBSTITUTION; EDITORIAL; HUMAN; INTERMETHOD COMPARISON; METHODOLOGY; NAUSEA; NEUROPATHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; THROMBOPHLEBITIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 24044534798     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi288     Document Type: Editorial

References (23)

1. Fisher B, Mamounas EP. Preoperative chemotherapy: A model for studying the biology and therapy of primary breast cancer. J Clin Oncol 1995; 13: 537-540.
2. Bonadonna G, Valagussa P, Brambilla C et al. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16: 93-100.
3. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
4. Chua S, Smith IE, A'Hern RP et al. Neoadjuvant vinorelbine/epirubicin versus standard adriamycin/cyclophosphamide in operable breast cancer: analysis of response and tolerability in a randomised phase 3 trial (TOPIC 2). Ann Oncol 2005; 16: 1435-1441.
5. Smith IC, Heys SD, Hutcheon AW et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456-1466.
6. Hutcheon AW, Heys SD, Sarkar TK et al. Docetaxel primary chemotherapy in breast cancer: A five year update of the Aberdeen trial. Breast Cancer Res Treat 2003; 82: S9 (Abstr 11).
7. Evans TRJ, Yellowlees A, Foster E et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An Anglo-Celtic Cooperative Oncology group study. J Clin Oncol 2005; 23: 2988-2995.
8. Untch M, Konecny G, Ditsch N, Sorokina Y. Dose-dense sequential epirubicin-paclitaxel as preoperative treatment of breast cancer: results of a randomised AGO study. Proc Am Soc Clin Oncol 2002; 21: 34a (Abstr 133).
9. Fumoleau P, Tubiana-Hulin M, Romieu G et al. A randomized phase II study of 4 or 6 cycles of adriamycin/paclitaxel as neoadjuvant treatment of breast cancer. Breast Cancer Res Treat 2001; 69: 298 (Abstr 508).
10. Dieras V, Fumoleau P, Romieu G et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004; 22: 4958-4965.
11. von Minckwitz G, Costa SD, Raab G et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase IIb study. J Clin Oncol 2001; 19: 3506-3515.
12. von Minckwitz G, Raab G, Caputo A et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. J Clin Oncol 2005; 23: 2676-2685.
13. Luporsi E, Vanlemmens L, Coudert B et al. Six cycles of FEC 100 vs. 6 cycles of epirubicin-docetaxel (ED) as neoadjuvant chemotherapy in operable breast cancer patients: Preliminary results of a randomised phase II trial of Girec S01. Proc Am Soc Clin Oncol 2000; 19: 88a (Abstr 355).
14. Buzdar AU, Singletary SE, Theriault RL et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999; 17: 3412-3417.
15. Green MC, Buzdar AU, Smith T, Ibrahim NK. Weekly paclitaxel (P) followed by FAC as primary systemic therapy of perable breast cancer improves pathological complete remission rates when compared to every 3-week P therapy followed by FAC-final results of a prospective phase III randomized trial. Proc Am Soc Clin Oncol 2002; 21: 35a (Abstr 135).
16. Smith IE, A'Hern RP, Coombes GA et al. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol 2004; 15: 751-758.
17. Bear H, Anderson S, Smith RE et al. A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: Results of NSABP B-27. Breast Cancer Res Treat 2004; 88: S16 (Abstr 26).
18. Bear HD, Anderson S, Brown A et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21: 4165-4174.
19. Colleoni M, Viale G, Zahrieh D et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: A study of preoperative treatment. Clin Cancer Res 2004; 10: 6622-6628.
20. Buzdar AU, Valero V, Theriault RL et al. Pathological complete response to chemotherapy is related to hormone receptor status. Breast Cancer Res Treat 2003; 82: S69 (Abstr 302).
21. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathological complete remission after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor-2 positive operable breast cancer. J Clin Oncol 2005; 23: 3676-3685.
22. http://www.asco.org/ac/1,1003,_12-002511-00_18-0034-00_19-005813,00.asp
23. Baselga J, Arteaga CL. Clinical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23: 2445-2459.